Table 3.
Results
| Ref. | Tumor response criteria | Tumor response (%) | Median overall survival (mo) | Local control | Toxicity scale | Grade 3-4 toxicity |
| Koong et al[17], 2004 | - | NR | 11.0 | LP: 20%1 | RTOG | 0% |
| Koong et al[18], 2005 | - | NR | 7.7; 1-yr: 15% | LP: 6.2%2 | RTOG | Acute: Gastroparesis:10.5%3 |
| Schellenberg et al[19], 2008 | - | NR | 11.4; 1 yr: 50% | LP: 19% | CTC 3.0 | Acute: gastric ulcer: 6.2%; Late: duodenal stenosis: 6.2%; Duodenal perforation: 6.2%4 |
| Seo et al[20], 2009 | RECIST | 68 (PR: 68) | 14.0; 1 yr: 60% | LP: 44% LPFS (1-yr): 70.2 %; | RTOG | Acute: duodenal obstruction: 3.3%; Late: 0% |
| Goyal et al[21], 2012 | RECIST | 44 (CR: 13, PR: 31) | 14.45; 1 yr: 56% | LPFS (1-yr): 65% LPFS (median): 11.4 mo | CTC 3.0 | GI ulcer: 16%6 |
1
Local progressions: 0% in patients receiving 25 Gy;
2
In patients receiving RRS;
3
Unreported rate of late duodenal ulcers;
4
Five duodenal ulcers were classified G2;
5
14.8 mo in M0 patients;
6
Asymptomatic pyloric ulcer: 5.7%. CR: Complete response; GI: Gastrointestinal; LP: Local progression; LPFS: Local progression free survival; NR: Not reported; PR: Partial response.